DDrare: Database of Drug Development for Rare Diseases

331. 特発性多中心性キャッスルマン病
［臨床試験数：30，薬物数：44（DrugBank：23），標的遺伝子数：30，標的パスウェイ数：148］

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Best Supportive Care (BSC); Bevacizumab; Bortezomib; CNTO 328; CNTO328; CX-4945 oral formulation; Cetuximab; Chimeric murine human anti-IL-6 monoclonal antibody; Cyclophosphamide; Dexamethason; Doxorubicin; Doxorubicin Hydrochloride; Etoposide; Filgrastim; Filgrastim (G-CSF); G-CSF; Hyaluronidase; Interferon-alpha; Liposomal Doxorubicin; Methotrexate; Nelfinavir; Other: Laboratory Biomarker Analysis; Other: Observation Only; Other: Pharmacological Study; Pomalidomide; Prednisone; Rituximab; Rituximab or Rituximab Hyaluronidase Human; RoActemra; SILTUXIMAB; Siltuximab; Sirolimus; Suramin; Temsirolimus; Thalidomide; Thalidomide, cyclophosphamide and prednisone; Tocilizumab; Tocilizumab [RoActemra/Actemra]; Valganciclovir; Valganciclovir (VGC); Valproic Acid; Valproic acid; Vincristine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03043105 (ClinicalTrials.gov)	January 1, 2017	31/1/2017	TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Multicentric Castleman Disease	Drug: Thalidomide , cyclophosphamide and prednisone	Peking Union Medical College Hospital	NULL	Active, not recruiting	18 Years	N/A	All	25	Phase 2	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03043105
(ClinicalTrials.gov)

January 1, 2017

31/1/2017

TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Multicentric Castleman Disease

Drug: Thalidomide , cyclophosphamide and prednisone

Peking Union Medical College Hospital

NULL

Active, not recruiting

18 Years

N/A

All

Phase 2

China